Drug research

XEN1101

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Azetukalner

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic SeizuresNCT05667142	XENE	Phase 3	Recruiting	2027-04Estimated
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset SeizuresNCT05614063	XENE	Phase 3	Completed	2026-01-12Actual
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)NCT05716100	XENE	Phase 3	Recruiting	2026-10Estimated
A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal EpilepsyNCT03796962	XENE	Phase 2	Active not recruiting	2021-09-02Actual
An Open-label Study of XEN1101 in EpilepsyNCT05718817	XENE	Phase 3	Enrolling by invitation	2033-04Estimated

XENERecruitingPrimary completion: 2027-04 · Estimated

Trial details

XENECompletedPrimary completion: 2026-01-12 · Actual

Trial details

XENERecruitingPrimary completion: 2026-10 · Estimated

Trial details

XENEActive not recruitingPrimary completion: 2021-09-02 · Actual

Trial details

XENEEnrolling by invitationPrimary completion: 2033-04 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.